These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19409930)

  • 21. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.
    Clarke DK; Cooper D; Egan MA; Hendry RM; Parks CL; Udem SA
    Springer Semin Immunopathol; 2006 Nov; 28(3):239-53. PubMed ID: 16977404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice.
    Ajbani SP; Velhal SM; Kadam RB; Patel VV; Bandivdekar AH
    Int J Biol Macromol; 2015 Nov; 81():794-802. PubMed ID: 26361864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes.
    Gall JG; Lizonova A; EttyReddy D; McVey D; Zuber M; Kovesdi I; Aughtman B; King CR; Brough DE
    Mol Biotechnol; 2007 Mar; 35(3):263-73. PubMed ID: 17652790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. System for efficient helper-dependent minimal adenovirus construction and rescue.
    Hillgenberg M; Schnieders F; Löser P; Strauss M
    Hum Gene Ther; 2001 Apr; 12(6):643-57. PubMed ID: 11426464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions.
    Virnik K; Ni Y; Berkower I
    Vaccine; 2013 Apr; 31(17):2119-25. PubMed ID: 23474312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes.
    Eloit M; Adam M; Gallais I; Fournier A
    J Virol; 1997 Jul; 71(7):5375-81. PubMed ID: 9188608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
    McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
    Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
    Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
    DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).
    Barouch DH; Liu J; Peter L; Abbink P; Iampietro MJ; Cheung A; Alter G; Chung A; Dugast AS; Frahm N; McElrath MJ; Wenschuh H; Reimer U; Seaman MS; Pau MG; Weijtens M; Goudsmit J; Walsh SR; Dolin R; Baden LR
    J Infect Dis; 2013 Jan; 207(2):248-56. PubMed ID: 23125443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
    Alexander J; Mendy J; Vang L; Avanzini JB; Garduno F; Manayani DJ; Ishioka G; Farness P; Ping LH; Swanstrom R; Parks R; Liao HX; Haynes BF; Montefiori DC; LaBranche C; Smith J; Gurwith M; Mayall T
    PLoS One; 2013; 8(12):e82380. PubMed ID: 24312658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the expression and immunogenicity of wild-type and sequence-modified HIV-1 gag genes in a recombinant Sendai virus vector.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Li H; Li Z; Zhong R; Zeng Y
    Curr HIV Res; 2010 Apr; 8(3):199-206. PubMed ID: 20158459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.
    Lin SW; Hensley SE; Tatsis N; Lasaro MO; Ertl HC
    J Clin Invest; 2007 Dec; 117(12):3958-70. PubMed ID: 18008010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.
    Coughlan L
    Front Immunol; 2020; 11():909. PubMed ID: 32508823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.
    Yoshida T; Okuda K; Xin KQ; Tadokoro K; Fukushima J; Toda S; Hagiwara E; Hamajima K; Koshino T; Saito T
    Clin Exp Immunol; 2001 Jun; 124(3):445-52. PubMed ID: 11472406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen.
    Herath S; Le Heron A; Colloca S; Bergin P; Patterson S; Weber J; Tatoud R; Dickson G
    Vaccine; 2015 Dec; 33(51):7283-7289. PubMed ID: 26546736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.